No Data
No Data
Alvotech Says AVT03 Marketing Application Accepted by European Medicines Agency
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia and Xgeva
Express News | European Medicines Agency Confirms Acceptance of Marketing Application for Avt03, a Proposed Biosimilar to Prolia® and Xgeva®
Express News | Alvotech SA - Initiates Confirmatory Patient Study for Avt16, a Proposed Biosimilar to Entyvio®
Private Equity Firms Invested in Alvotech (NASDAQ:ALVO) Copped the Brunt of Last Week's US$178m Market Cap Decline
UnitedHealth Follows Competitors, Replaces Humira With Lower-Cost Biosimilars
No Data
No Data